Potential therapeutical effects of topical halofuginone hydrobromide in keloid management.
Lista
Simone
S
Emanuele
Enzo
E
D000287:Administration, Topical; D049109:Cell Proliferation; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007627:Keloid / Q000188:drug therapy*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008954:Models, Biological; D008962:Models, Theoretical; D010880:Piperidines / Q000008:administration & dosage* / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D052999:Quinazolinones / Q000008:administration & dosage* / Q000627:therapeutic use*
D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D052999:Quinazolinones; D020778:Matrix Metalloproteinase 2; C010176:halofuginone